Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wada, M.
Right arrow Articles by Nagano, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wada, M.
Right arrow Articles by Nagano, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: III13-III17
© 2003 European Renal Association-European Dialysis and Transplant Association

Original Article

Control of parathyroid cell growth by calcimimetics

Michihito Wada and Nobuo Nagano

Pharmaceutical Development Laboratories, Kirin Brewery Co. Ltd, Takasaki-shi, Gunma, Japan

Parathyroid cell hyperplasia is commonly observed in patients with chronic renal insufficiency and largely accounts for refractory secondary hyperparathyroidism. Calcimimetics are newly synthesized compounds that activate a calcium receptor on the parathyroid cell and can suppress parathyroid hormone secretion. The calcimimetic compound AMG 073 has been examined in clinical trials, and the data obtained so far demonstrate that the compound can lower the circulating levels of parathyroid hormone and calcium–phosphorus product in patients with secondary hyperparathyroidism. Furthermore, experimental evidence indicates that calcimimetics have the potential to inhibit parathyroid cell proliferation and block the progression of parathyroid hyperplasia. These beneficial effects, especially the potential to control parathyroid cell proliferation, would place calcimimetics among the essential therapeutic agents for treating secondary hyperparathyroidism.

Keywords: calcimimetics; calcium receptor; chronic renal insufficiency; hyperparathyroidism; parathyroid hormone; parathyroid hyperplasia

Correspondence and offprint requests to: M. Wada, PhD, Pharmaceutical Development Laboratories, Kirin Brewery Co. Ltd, Takasaki-shi, Gunma 370-1295, Japan. Email: wadam{at}kirin.co.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NDT PlusHome page
T. Date, Y. Kawashita, M. Matsuzaki, H. Kobayashi, and N. Nagano
The administration of cinacalcet hydrochloride just before a haemodialysis session suppresses the transient rise in intact parathyroid hormone induced by a low-calcium dialysate: when should cinacalcet hydrochloride be administered?
NDT Plus, September 6, 2008; (2008) sfn128v2.
[Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
E. F. Nemeth
Anabolic Therapy for Osteoporosis: Calcilytics
IBMS BoneKEy, June 1, 2008; 5(6): 196 - 208.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
T. Kawata, Y. Imanishi, K. Kobayashi, T. Kenko, M. Wada, E. Ishimura, T. Miki, N. Nagano, M. Inaba, A. Arnold, et al.
Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism
Eur. J. Endocrinol., October 1, 2005; 153(4): 587 - 594.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
G. J. Strewler
A 64-Year-Old Woman With Primary Hyperparathyroidism
JAMA, April 13, 2005; 293(14): 1772 - 1779.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.